Barclays Maintains Underweight on Janux Therapeutics, Raises Price Target to $15

Benzinga · 4d ago
Barclays analyst Etzer Darout maintains Janux Therapeutics (NASDAQ:JANX) with a Underweight and raises the price target from $14 to $15.